INVESTOR RELATIONS

PRESS RELEASES

22-Dec-2005 AMARIN CORPORATION RAISES $26.4 MILLION IN PRIVATE PLACEMENT
19-Dec-2005 AMARIN CORPORATION PLC ANNOUNCES $26.4 MILLION PRIVATE PLACEMENT
15-Dec-2005 AMARIN ANNOUNCES COMMENCEMENT OF EUROPEAN PIVOTAL PHASE III CLINICAL TRIAL FOR MIRAXION IN HUNTINGTON'S DISEASE
16-Nov-2005 AMARIN ANNOUNCES SIGNIFICANT NEUROPROTECTIVE EFFECTS OF MIRAXION
9-Nov-2005 AMARIN REPORTS THIRD QUARTER 2005 RESULTS
7-Nov-2005 AMARIN CORPORATION PLC ANNOUNCES THIRD QUARTER 2005 EARNINGS CONFERENCE CALL
7-Nov-2005 AMARIN CORPORATION TO PRESENT AT SG COWEN & CO. 6TH ANNUAL GLOBAL HEALTH CARE CONFERENCE
2-Nov-2005 AMARIN CORPORATION TO PRESENT AT RODMAN & RENSHAW TECHVEST 7TH ANNUAL HEALTHCARE CONFERENCE
2-Nov-2005 AMARIN ANNOUNCES APPOINTMENT OF TOM MAHER AS GENERAL COUNSEL
24-Oct-2005 AMARIN CORPORATION TO PRESENT AT C.E. UNTERBERG, TOWBIN EMERGING GROWTH LIFE SCIENCES CONFERENCE
18-Oct-2005 AMARIN CORPORATION TO PRESENT AT 2005 BIO INVESTOR FORUM
17-Oct-2005 AMARIN CORPORATION TO PRESENT AT DAVY SMALL & MID CAP CONFERENCE
12-Oct-2005 AMARIN REPORTS ISSUANCE BY CRYSTAL RESEARCH ASSOCIATES, LLC OF EXECUTIVE INFORMATIONAL OVERVIEW® (EIO®)
4-Oct-2005 AMARIN CORPORATION TO PRESENT AT SACHS BLOOMBERG'S 5TH ANNUAL BIOTECH IN EUROPE INVESTOR FORUM
21-Sep-2005 AMARIN REPORTS INITIATION OF ENROLLMENT AND FIRST PATIENT DOSING IN PIVOTAL PHASE III CLINICAL TRIALS FOR MIRAXION IN HUNTINGTON’S DISEASE
12-Sep-2005 AMARIN RECEIVES SPECIAL PROTOCOL ASSESSMENT FROM FDA FOR TWO PIVOTAL PHASE III CLINICAL TRIALS FOR MIRAXION IN HUNTINGTON'S DISEASE
16-Aug-2005 AMARIN ANNOUNCES APPOINTMENT OF DR. ANTHONY CLARKE AS VICE PRESIDENT CLINICAL DEVELOPMENT
4-Aug-2005 AMARIN ANNOUNCES APPOINTMENT OF DR. PREM LACHMAN
27-Jul-2005 AMARIN REPORTS SECOND QUARTER 2005 RESULTS
14-Jun-2005 AMARIN ANNOUNCES COMMENCEMENT OF RECRUITMENT BY HUNTINGTON STUDY GROUP FOR MIRAXION PHASE III CLINICAL TRIAL
Page 1 of 2